Status: Recruiting
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ashish ShahUpdated: May 28, 2026Locations: 1
Eligibility criteria
Patients 18-75 years old. [+10]
History of active other malignancy (other than non-melanoma skin cancers, cervic... [+20]